News for 'Mankind Pharma'

Electoral bonds: Who is lottery king Santiago Martin?

Electoral bonds: Who is lottery king Santiago Martin?

Rediff.com15 Mar 2024

Future Gaming and Hotel Services whose director is the lottery magnate Santiago Martin is the top purchaser of electoral bonds having purchased bonds worth Rs 1,368, according to data uploaded by the Election Commission of India on its website on Thursday.

India's Billionaire Club Has New Entrants

India's Billionaire Club Has New Entrants

Rediff.com9 Jan 2024

The IPO boom in 2023 added four new promoters to the billionaires' list.

'IPO market has bullish outlook in 2024'

'IPO market has bullish outlook in 2024'

Rediff.com12 Dec 2023

'A key reason for the strong interest in IPOs has been an increased focus on profitability and reasonable pricing of deals.'

Ballooning condom prices bring in regulator, 2 tiers likely

Ballooning condom prices bring in regulator, 2 tiers likely

Rediff.com2 Mar 2017

The National Pharmaceutical Pricing Authority has decided to have one price for basic utility condoms and the other for pleasure condoms.

Trade generics growth to dent value expansion of domestic drug market

Trade generics growth to dent value expansion of domestic drug market

Rediff.com2 Jan 2024

Rising penetration of trade generic medicines is eating into the value growth of the domestic pharmaceutical market, showed a recent analysis. According to a Kotak Institutional Equities analysis, 70-110 basis points (bps) annual dent is expected from trade generics and Jan Aushadhi on Indian Pharma Market (IPM) growth at least until FY27-28 (see chart). Trade generic medicines are those that are not pushed into the market through doctor promotions.

Drugs ban: These are the worst hit brands, companies

Drugs ban: These are the worst hit brands, companies

Rediff.com21 Mar 2016

Govt bans brands with annual sales worth Rs 3,728 crore.

Govt may now cap prices of antibiotics

Govt may now cap prices of antibiotics

Rediff.com7 Oct 2019

The intention of the government is to cap prices of drugs that are essential and which the public widely uses.

PE Big Bang: Record $8.2 bn investment in April-June

PE Big Bang: Record $8.2 bn investment in April-June

Rediff.com3 Jul 2018

While 2017 was a record year for private equity investments in India after $23.5 billion in 660 deals, 2018 too has begun with a bang.

Prices of key diabetes, cancer drugs may drop by 25%

Prices of key diabetes, cancer drugs may drop by 25%

Rediff.com8 Mar 2018

A recent report has suggested that future patent expires in the cardiac and anti-diabetes space would form a good opportunity for smaller firms, given their franchise in these segments.

Pharma firms to be hit as drug regulator caps prices

Pharma firms to be hit as drug regulator caps prices

Rediff.com19 Sep 2014

Currently, the govt directly caps prices of 348 formulations at the average price of all medicines in a particular segment with at least 1% market share

Price relief for diabetes patients as drugs go off patent

Price relief for diabetes patients as drugs go off patent

Rediff.com13 Jan 2020

At least two key drugs in the gliptin category have already gone off patent and cheaper variants are crowding the market. Also, several patent expiries are round the corner for the newest category of drugs - SGLT-2 inhibitors or gliflozins.

Drugs ban: Partial relief for Wockhardt, Glaxo & Griffon

Drugs ban: Partial relief for Wockhardt, Glaxo & Griffon

Rediff.com18 Mar 2016

The Delhi High Court on Friday stayed the ban on some fixed dose combination (FDC) drugs of Glaxo SmithKline, Wockhardt and Laboratories Griffon but said action against their sale could be taken in the absence of valid sale and marketing licence.

Revealed! The top JOBS of 2020

Revealed! The top JOBS of 2020

Rediff.com30 Dec 2020

Naukri.com's Hiring Outlook Survey for 2020 reveals the jobs and sectors that saw a surge in demand during the pandemic.

What India thinks of Sunny Leone

What India thinks of Sunny Leone

Rediff.com4 Feb 2016

As Sunny Leone's film, Mastizaade, hit screens amidst a wave of unprecedented social media support for her, Ritika Bhatia finds out what India thinks of the actor.

Managing Internet tech change wisely

Managing Internet tech change wisely

Rediff.com26 Mar 2021

Ajit Balakrishnan on learning from past technology revolutions.

Why 'She' is uncomfortable in Emami's basket of brands

Why 'She' is uncomfortable in Emami's basket of brands

Rediff.com21 Dec 2017

One of the reasons for the failure, say industry experts and financial analysts, is that Emami strayed too far from its core with sanitary napkins.

« Prev  |